Ann: Immutep receives FDA feedback for Efti development in MBC, page-28

It would be good to know the details of the FDA advice. It sounds like the company is doing its homework on trajectories of emerging therapies before deciding on the ph3. Current market conditions and persistent lack of strength in the stock have heightened the risks.

Certainly, if things don't improve and no partner emerges investors are going to be nervous on the ph3. On balance, I think we need a partner for it for no other reason than to calm nerves, validate the companies technology and put some backbone in the share price. Its past overdue! Now is the point where a deal of some sort has to be done in order for the company to progress properly into mid to late stage biotech, Imo.

Of course, if excellent results in the Keytruda combos keep coming and Lag3 registration kicks off market interest in Lag3 stocks then the share price could recover and go it alone ph3 may look less risky. I think by mid year we should have a clearer picture of where things stand.